Coya Therapeutics (NASDAQ:COYA) Upgraded at Wall Street Zen
by Doug Wharley · The Cerbat GemWall Street Zen upgraded shares of Coya Therapeutics (NASDAQ:COYA – Free Report) from a sell rating to a hold rating in a report issued on Saturday.
COYA has been the topic of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a report on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, March 23rd. D. Boral Capital reiterated a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a report on Friday, April 10th. Finally, Chardan Capital reissued a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research report on Monday, March 16th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $16.00.
View Our Latest Research Report on COYA
Coya Therapeutics Trading Up 4.4%
COYA stock opened at $4.99 on Friday. The firm has a market cap of $117.07 million, a PE ratio of -3.93 and a beta of 0.51. Coya Therapeutics has a 1 year low of $3.71 and a 1 year high of $7.75. The company has a fifty day simple moving average of $4.53 and a 200 day simple moving average of $5.28.
Coya Therapeutics (NASDAQ:COYA – Get Free Report) last posted its earnings results on Monday, March 16th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.26). Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. The company had revenue of $3.96 million for the quarter, compared to the consensus estimate of $1.93 million. As a group, analysts forecast that Coya Therapeutics will post -1.81 EPS for the current fiscal year.
Hedge Funds Weigh In On Coya Therapeutics
Several large investors have recently made changes to their positions in COYA. JPMorgan Chase & Co. bought a new stake in Coya Therapeutics during the 3rd quarter valued at approximately $28,000. CIBC Private Wealth Group LLC bought a new position in Coya Therapeutics in the 4th quarter worth approximately $47,000. Occudo Quantitative Strategies LP bought a new position in Coya Therapeutics in the 4th quarter worth approximately $66,000. Lantern Wealth Advisors LLC acquired a new position in shares of Coya Therapeutics during the third quarter worth approximately $66,000. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of Coya Therapeutics during the fourth quarter worth approximately $81,000. Institutional investors and hedge funds own 39.75% of the company’s stock.
Coya Therapeutics Company Profile
Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.
Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.